Loading…
Sanofi is projected to rise to $53.07 by 2027, a +21% move from its current price of $43.90. SNY is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $43.26 | $43.92 | $44.58 | +0.04% |
| Jul 14 | $43.01 | $43.93 | $44.87 | +0.08% |
| Jul 15 | $42.82 | $43.95 | $45.11 | +0.12% |
| Jul 16 | $42.67 | $43.97 | $45.31 | +0.15% |
| Jul 17 | $42.54 | $43.98 | $45.48 | +0.19% |
| Jul 18 | $42.42 | $44.00 | $45.65 | +0.23% |
| Jul 19 | $42.31 | $44.02 | $45.80 | +0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $42.31 | $44.02 | $45.80 | +0.27% |
| Week 2 | $41.73 | $44.14 | $46.68 | +0.54% |
| Week 3 | $41.32 | $44.26 | $47.40 | +0.82% |
| Week 4 | $40.99 | $44.38 | $48.04 | +1.09% |
| Week 5 | $40.72 | $44.50 | $48.62 | +1.36% |
| Week 6 | $40.49 | $44.62 | $49.17 | +1.64% |
| Week 7 | $40.28 | $44.74 | $49.69 | +1.91% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sanofi (SNY) is a healthcare company that engages in the research, development, manufacture, and marketing of therapeutic solutions. Its focus includes immunology and inflammation, rare diseases neurology, oncology, and other vaccines, with pediatric vaccines for poliomyelitis, pertussis, and Haemophilus influenzae type b (Hib); RSV protection and hexavalent vaccines that include hepatitis A, typhoid, yellow fever, and rabies vaccines.
Sanofi maintains collaboration and license agreements with Exscientia to develop up to 15 novel small-molecule programs for oncology and immunology; ABL Bio, Innate Pharma; and collaborations with Atomwise and Insilico Medicine, Kymera Therapeutics, Nurix Therapeutics, Denali Therapeutics, and Adagene. It also has a collaboration with Scribe Therapeutics for genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574 for ulcerative colitis and Crohn’s disease; and a co-promotion service agreement with Provention Bio for teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011.
Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Sanofi operates in the Healthcare sector as a large-cap pharmaceutical company with a broad portfolio spanning vaccines, immunology, oncology, and rare diseases. Its stock is listed under the symbol SNY and currently trades with a price of $41.78 and a market capitalization of $100.01B, ranking 144 by market size.
The stock trades in a traditionally defensive space, with a current price near a defined support at $41.78 and a nearby resistance at $45.02. The 30-day price range spans from $37.93 to $46.02, reflecting modest near-term volatility within a broad consolidation.
Forecasts project a multi-year ascent in value, with the average price rising from $41.78 in 2026 to $68.02 by 2030 and to $262.32 by 2050, accompanied by progressively higher ROIs (0% in 2026 up to 527.9% by 2050). The sentiment outlook shifts to bullish over the longer horizon, signaling meaningful upside potential alongside inherent uncertainty in any forecast.
A major floor 9.8% below — a decisive break under it would weaken the trend.
The nearest floor, 5.9% below — buyers have tended to step in here.
Price is pressing into resistance (2.6% away) — a breakout level to watch.
A major ceiling 9.7% above — clearing it would confirm fresh momentum.
Key SNY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SNY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $43.15 | Buy | $43.25 | Buy |
| MA 10 | $42.96 | Buy | $43.03 | Buy |
| MA 20 | $42.86 | Buy | $43.03 | Buy |
| MA 50 | $43.47 | Buy | $43.69 | Buy |
| MA 100 | $44.92 | Sell | $44.75 | Sell |
| MA 200 | $46.82 | Sell | $46.25 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.04 | Neutral |
| Stoch RSI (14) | 87.26 | Sell |
| CCI (20) | 56.66 | Neutral |
| Williams %R (14) | -15.56 | Info |
| MACD (12,26,9) | 0.19 | Buy |
| ROC (12) | 4.57 | Buy |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 84.44 | Sell |
| TRIX (15) | -0.11 | Sell |
| Awesome (5,34) | -0.16 | Sell |
| Ultimate (7,14,28) | 56.31 | Neutral |
| Momentum (10) | 1.70 | Buy |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 43.54 | Buy |
| ADX (14) | 10.28 | Neutral |
| ATR (14) | 0.65 | Info |
The 30-day technical picture is bearish, with RSI(14) at 40, indicating modest downside pressure. The stock sits below the 50- and 200-day simple moving averages, with the SMA50 at $44.65 and the SMA200 at $47.10.
Near-term support is at $41.78 and resistance at $45.02, framing a 30-day range of $37.93 to $46.02. A move toward the resistance level could be a catalyst if buyers re-enter, while breaking below the support might invite additional selling pressure.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $41.33 | $43.90 | $57.18 | 0% | Neutral | |
| $43.46 | $53.07 | $67.75 | +21% | Bullish | |
| $47.91 | $59.60 | $78.14 | +36% | Bullish | |
| $55.50 | $70.11 | $93.88 | +60% | Bullish | |
| $57.73 | $73.91 | $100.74 | +68% | Bullish | |
| $58.18 | $75.39 | $104.39 | +72% | Bullish | |
| $62.29 | $81.63 | $114.64 | +86% | Bullish | |
| $65.19 | $86.33 | $122.82 | +97% | Bullish | |
| $76.48 | $102.29 | $147.25 | +133% | Bullish | |
| $85.95 | $116.04 | $168.91 | +164% | Bullish | |
| $107.03 | $150.71 | $229.89 | +243% | Bullish | |
| $194.79 | $294.18 | $481.01 | +570% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $41.33 | $43.90 | $51.42 | +0.00% |
| August 2026 | $37.78 | $44.23 | $52.90 | +0.74% |
| September 2026 | $38.66 | $45.48 | $54.82 | +2.82% |
| October 2026 | $38.43 | $45.38 | $55.07 | -0.20% |
| November 2026 | $38.29 | $45.38 | $55.36 | -0.01% |
| December 2026 | $39.22 | $46.63 | $57.18 | +2.76% |
Click any year to see its month-by-month SNY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, SNY could reach as high as $57.18, with a base case around $43.90 and support toward $41.33 — roughly 0% from $43.90. A consolidation phase looks the most probable path here.
Expect SNY to range from $43.46 to $67.75 through 2027. The $53.07 average target implies a +21% move from current prices. That is up +21% on the projected 2026 average. Momentum favours further upside here.
The SNY price prediction for 2028 points to an average of $59.60 (low $47.91, high $78.14) — a potential gain of +36% on today's $43.90. Buyers look set to stay in control over this stretch.
In 2029, SNY is projected to trade between $55.50 and $93.88, averaging $70.11 — a potential gain of +60% from today's $43.90. That is up +18% on the projected 2028 average. Momentum favours further upside here.
Sanofi's 2030 outlook centres on $73.91, within a $57.73 to $100.74 range. That is up +5% on the projected 2029 average. That marks a +68% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, SNY could reach as high as $104.39, with a base case around $75.39 and support toward $58.18 — roughly +72% from $43.90. Momentum favours further upside here.
Expect SNY to range from $62.29 to $114.64 through 2032. The $81.63 average target implies a +86% move from current prices. That is up +8% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The SNY price prediction for 2033 points to an average of $86.33 (low $65.19, high $122.82) — a potential gain of +97% on today's $43.90. Momentum favours further upside here.
In 2034, SNY is projected to trade between $76.48 and $147.25, averaging $102.29 — a potential gain of +133% from today's $43.90. That is up +18% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Sanofi's 2035 outlook centres on $116.04, within a $85.95 to $168.91 range. That is up +13% on the projected 2034 average. That marks a +164% change versus current levels. Momentum favours further upside here.
By 2040, SNY could reach as high as $229.89, with a base case around $150.71 and support toward $107.03 — roughly +243% from $43.90. Buyers look set to stay in control over this stretch.
Expect SNY to range from $194.79 to $481.01 through 2050. The $294.18 average target implies a +570% move from current prices. That is up +95% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in SNY today (≈ 22.779043 SNY) could be worth
$6,701.05
+$5,701.05 (+570%) by 2050 · US Dollar
Based on the average projected SNY price of $294.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SNYwould be worth at today's price.
$1,000 invested in SNY on Jul 10, 2025 (≈ 20.267531 SNY) would be worth
$889.74
-$110.26 (-11.0%) today · 0.89× · US Dollar
Based on a SNY entry price of $49.34 vs. today's $43.9.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $43.16 | $1,017.15 | +1.7% |
| 1 month ago | $43.57 | $1,007.57 | +0.8% |
| 3 months ago | $46.76 | $938.84 | -6.1% |
| 6 months ago | $47.6 | $922.27 | -7.8% |
| 1 year ago | $49.34 | $889.74 | -11.0% |
| All time (5.0y) ago | $52.27 | $839.87 | -16.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SNY forecast.
Our base-case forecast reaches $88.00 around 2034.
Implied market cap at $88.00: $210.65B
The multi-year forecast points to a bullish trajectory beyond 2026, with 2026's average price at $41.78 and a max of $54.82, yielding 0% ROI. From 2027 onward, the model envisions a steady rise in value: 2027 avg $49.48 with ROI 18.4%, 2028 avg $56.29 with ROI 34.7%, 2029 avg $66.02 with ROI 58%, 2030 avg $68.02 with ROI 62.8%, and 2031–2035 continuing to climb with increasing ROIs (2031 ROI 66.6%, 2032 ROI 81%, 2033 ROI 88.3%, 2034 ROI 124.9%, 2035 ROI 154.2%). The long-range outlook extends to 2040 (avg $137.24, ROI 228.5%) and 2050 (avg $262.32, ROI 527.9%), all under the bullish sentiment umbrella.
These figures illustrate substantial upside potential while acknowledging that forecasts are estimates, not guarantees, and carry inherent uncertainty.
Tap a question to reveal the answer.
2030: min $53.10, avg $68.02, max $92.79, ROI 62.8%, sentiment BULLISH.
The forecast shows neutral in 2026 (avg $41.78, ROI 0) and then bullish from 2027 onward, with rising ROIs (18.4% in 2027, 34.7% in 2028, 58% in 2029, up to 62.8% in 2030 and 527.9% by 2050). These are estimates, not guarantees.
Yes. The forecast maximums show $106.29 in 2032, $111.98 in 2033, and $135.35 in 2034, indicating it can exceed $100 in the early-to-mid 2030s.
Current price: $41.78. Market cap: $100.01B.
Bearish sentiment with RSI(14) at 40. SMA50 is $44.65, SMA200 is $47.10. Support is $41.78 and resistance is $45.02; 30-day range is $37.93 to $46.02.
Sanofi Community Discussion
0Share your Sanofi price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.